ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus …
Writing Committee Members, VV McLaughlin… - Circulation, 2009 - Am Heart Assoc
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension | Circulation Science
Volunteer Warning signs SearchSearch Advanced Search Donate Circulation logo Hello Guest …
Volunteer Warning signs SearchSearch Advanced Search Donate Circulation logo Hello Guest …
Pulmonary arterial hypertension
VV McLaughlin, MD McGoon - Circulation, 2006 - Am Heart Assoc
elevated in patients with PAH, 13 and clearance of endothelin in the pulmonary vasculature
is reduced. 14 Endothelin acts at 2 different receptors: ETA receptors on vascular smooth …
is reduced. 14 Endothelin acts at 2 different receptors: ETA receptors on vascular smooth …
Updated treatment algorithm of pulmonary arterial hypertension
The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple
and in some ways conflicting. The treatment algorithm usually includes different types of …
and in some ways conflicting. The treatment algorithm usually includes different types of …
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial
DB Badesch, VF Tapson, MD McGoon… - Annals of internal …, 2000 - acpjournals.org
Background: Pulmonary hypertension is a progressive and often fatal complication of the
scleroderma spectrum of disease for which no treatment has been proven effective in a …
scleroderma spectrum of disease for which no treatment has been proven effective in a …
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy
VV McLaughlin, A Shillington, S Rich - Circulation, 2002 - Am Heart Assoc
Background—Primary pulmonary hypertension (PPH) is a severe and progressive disease.
Without treatment, the median survival is 2.8 years, with survival rates of 68%, 48%, and …
Without treatment, the median survival is 2.8 years, with survival rates of 68%, 48%, and …
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo …
N Galič, H Olschewski, RJ Oudiz, F Torres, A Frost… - Circulation, 2008 - Am Heart Assoc
Background—Ambrisentan is a propanoic acid–based, A-selective endothelin receptor
antagonist for the once-daily treatment of pulmonary arterial hypertension. Methods and …
antagonist for the once-daily treatment of pulmonary arterial hypertension. Methods and …
[HTML][HTML] Selexipag for the treatment of pulmonary arterial hypertension
O Sitbon, R Channick, KM Chin, A Frey… - … England Journal of …, 2015 - Mass Medical Soc
Background In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist,
was shown to be beneficial in the treatment of pulmonary arterial hypertension. Methods In …
was shown to be beneficial in the treatment of pulmonary arterial hypertension. Methods In …
[HTML][HTML] Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension
N Galič, JA Barberŕ, AE Frost… - … England Journal of …, 2015 - Mass Medical Soc
Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
VV McLaughlin, RJ Oudiz, A Frost… - American journal of …, 2006 - atsjournals.org
Rationale: Small, open-label studies suggest that combinations of existing therapies may be
effective for pulmonary arterial hypertension (PAH). Objective: To evaluate the safety and …
effective for pulmonary arterial hypertension (PAH). Objective: To evaluate the safety and …
Sitaxsentan therapy for pulmonary arterial hypertension
…, R Oudiz, S Shapiro, V McLaughlin… - American journal of …, 2004 - atsjournals.org
Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the
vasoconstrictor effects of endothelin-A while maintaining the vasodilator/clearance functions …
vasoconstrictor effects of endothelin-A while maintaining the vasodilator/clearance functions …